Physiology and medicine

Physiology and Medicine

Volumn , Issue , 2007, Pages 1-302

  Torshin, Ivan Yu ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892345788     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (285)

1. McCarthy JJ. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet. 2004; 41 (5): 334-341.
2. Hattersley AT. What makes a good genetic association study?. Lancet. 2005; 366 (9493): 1315-1323.
3. Herrington D. Eliminating the improbable: Sherlock Holmes and standards of evidence in the genomic age. Circulation. 2005; 112 (14): 2081-2084.
4. Coghlan A. One million people, one medical gamble New Scientist 20 Jan 2006 (see the news item at http://www.newscientist.com/article.ns?id=mg18925353.800)
5. Strange K. The end of "naive reductionism": rise of systems biology or renaissance of physiology? Am J Physiol Cell Physiol. 2005;288(5):C968-C974.
6. Wang M. Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res. 2005; 19 (3): 173-182.
7. Smith R. Unscientific practice flourishes in science. BMJ 1998; 316 (7137): 1036.
8. Fahey T. Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ 1995; 311 (7012): 1056-9.
9. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005; 2 (8): e124.
10. W. Osler. The evolution of modern medicine (lectures at Yale University, 1913), available at http://etext.lib.virginia.edu/toc/modeng/public/OslEvol.html
11. Pavlov I.P. Pavlovskie sredy (in 3 volumes), volume 3. Izd Akademii Nauk SSSR, 1949, Moscow-Leningrad.
12. Pavlov I.P. Complete works (in 6 volumes). Izd Akademii Nauk SSSR, 1952, Moscow-Leningrad.
13. The Yellow Emperor's Classic of Internal Medicine. Huang Ti (The Emperor of China), Ni Maoshing (Tr.), Shambhala Pub, Boston, MA, 1995
14. Reid, Daniel J., Chinese Herbal Medicine. Shambhala Pub, Boston, MA, 1993
15. H. Beinfeld, E. Korngold. A Guide to Chinese Medicine Ballantine Books, NY, 1991
16. D Unglaub, P. Silverthorn. Human Physiology: An Integrated Approach (1st ed), Prentice Hall, 1997
17. Cannon WB The wisdom of the body. Norton Pubs, 1932.
18. Committee on Quality of Health Care in America, L Kohn, J Corrigan, M Donaldson (eds). To Err Is Human: Building a Safer Health System. Institute of Medicine (2000), http://books.nap.edu/books/03090681/html/index.html
19. Bachmann LM, Puhan MA, ter Riet G, Bossuyt PM. Sample sizes of studies on diagnostic accuracy: literature survey. BMJ. 2006; 332 (7550): 1127-1129.
20. S. Nussey, S. Whitehead. Endocrinology: An integrated approach, BIOS Scientific publishers, 2001.
21. Diekman MJ, van der Put NM, Blom HJ, Tijssen JG, Wiersinga WM. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol. 2001; 54 (2): 197-204.
22. Hustad S, Nedrebo BG, Ueland PM, Schneede J, Vollset SE, Ulvik A, Lien EA. Phenotypic expression of the methylenetetrahydrofolate reductase 677C-->T polymorphism and flavin cofactor availability in thyroid dysfunction. Am J Clin Nutr 2004; 80: 1050-1057.
23. B. Barnes. Hypothyroidism: the unsuspected illness, Harper-Collins, USA, 1976.
24. Pekarski S. A gravitational hypothesis of essential hypertension as a natural adaptation to increased gravitational stress. Med Sci Monit. 2004;10(6):HY27-32.
25. Samaras T, Elrick H, Storms L. Is short height really a risk factor for coronary heart disease and stroke mortality? Med Sci Monit, 2004; 10(4): RA63-76
26. Gallerani M, Boari B, de Toma D, Salmi R, Manfredini R. Seasonal variation in the occurrence of deep vein thrombosis. Med Sci Monit. 2004;10(5):CR191-6.
27. Chong N, Codd V, Chan D, Samani N. Circadian clock genes cause activation of the human PAI-1 gene promoter with 4G/5G allelic preference. FEBS Lett. 2006; 580 (18): 4469-72.
28. Whincup P, Gilg J, Emberson J, Jarvis M, Feyerabend C, Bryant A, Walker M, Cook D. Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. BMJ 2004; 329 (7459): 200-5.
29. Panagiotakos DB, Pitsavos C, Polychronopoulos E, Chrysohoou C, Zampelas A, Trichopoulou A. Can a Mediterranean diet moderate the development and clinical progression of coronary heart disease? A systematic review. Med Sci Monit. 2004 Aug;10(8):RA193-8.
30. Trichopoulou A, Orfanos P, Norat T, Bueno-de-Mesquita B, Ocke MC, Peeters PH, van der Schouw YT, Boeing H, Hoffmann K et al. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. BMJ. 2005 Apr 30; 330 (7498): 991-997.
31. Habana P, Klvanova J, Zidekova E, Nagyova A. Dietary supplementation with olive oil leads to improved lipoprotein spectrum and lower n-6 PUFAs in elderly subjects. Med Sci Monit, 2004; 10(3): PI49-54
32. Mattson MP, Wan R. Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems. J Nutr Biochem. 2005 Mar;16(3):129-37.
33. Kraus WE, Douglas PS. Where does fitness fit in?. N Engl J Med. 2005; 353 (5): 517-9.
34. Snyder E, Beck K, Dietz N, Eisenach J, Joyner M, Turner S, Johnson B. Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans. J Physiol. 2006 Feb 15; 571: 121-130.
35. Gennari F, Adrogue H, Galla J, Madias N (eds). Acid-Base Disorders and Their Treatment. Taylor&Francis, 2005.
36. Vasiliauskas D, Jasiukeviciene L. Impact of a correct breathing stereotype on pulmonary minute ventilation, blood gases and acid-base balance in post-myocardial infarction patients. Eur J Cardiovasc Prev Rehabil. 2004; 11 (3): 223-7.
37. Vaananen H, Syrjala H, Rahkila P, Vuori J, Melamies L, Myllyla V, Takala T. Serum carbonic anhydrase III and myoglobin concentrations in acute myocardial infarction. Clin Chem. 1990 Apr;36(4):635-8.
38. Kuppuswamy VC, Gupta S. Antibiotic therapy for coronary heart disease: The myth and the reality. Drugs Today (Barc). 2005 Oct;41(10):677-85.
39. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG. Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg. 2006; 31 (4): 386-93.
40. Pihlstrom B, Michalowicz B, Johnson N. Periodontal diseases. Lancet. 2005; 366 (9499): 1809-20.
41. Beck JD, Offenbacher S. Systemic effects of periodontitis: epidemiology of periodontal disease and cardiovascular disease. J Periodontol. 2005;76(11 Suppl):2089-100.
42. Manuck SB, Kaplan JR, Matthews KA. Behavioral antecedents of coronary heart disease and atherosclerosis. Arteriosclerosis. 1986; 6 (1): 2-14.
43. Kiecolt-Glaser J, Loving T, Stowell J, Malarkey W, Lemeshow S, Dickinson S, Glaser R. Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry. 2005; 62 (12): 1377-84.
44. von Kanel R, Kudielka BM, Schulze R, Gander ML, Fischer JE. Hypercoagulability in working men and women with high levels of panic-like anxiety. Psychother Psychosom. 2004; 73 (6): 353-60.
45. Andre-Petersson L, Hedblad B, Janzon L, Steen G. Asymptomatic atherosclerosis and myocardial infarction: risk modified by ability to adapt to stressful situations. Med Sci Monit. 2004 Oct;10(10):CR549-56.
46. Sturmer T, Hasselbach P, Amelang M. Personality, lifestyle, and risk of cardiovascular disease and cancer: follow-up of population based cohort. BMJ. 2006; 332 (7554): 1359.
47. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501-505.
48. Kannel W, Wolf P, Castelli W, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258:1183-1186.
49. Woodward M, Lowe G, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. Eur Heart J 1998; 19:55-62.
50. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118:956-963.
51. Retterstol L, Kierulf P, Pedersen J, Bohn M, Bakken A, Erikssen J, Berg K. Plasma fibrinogen level and long-term prognosis in Norwegian middle-aged patients with previous myocardial infarction. A 10 year follow-up study. J Intern Med. 2001; 249 (6): 511-8.
52. Retterstol L, Eikvar L, Bohn M, Bakken A, Erikssen J, Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction--a 10 year follow-up study. Atherosclerosis. 2002; 160 (2): 433-40.
53. Fancher TL, White RH, Kravitz RL. Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ. 2004; 329 (7470): 821.
54. Srinivasan S, Li S, Chen W, Boerwinkle E, Berenson G. R219K polymorphism of the ABCA1 gene and its modulation of the variations in serum high-density lipoprotein cholesterol and triglycerides related to age and adiposity in white versus black young adults. Metabolism. 2003; 52 (7): 930-4.
55. Williams MS, Bray PF. Genetics of arterial prothrombotic risk states. Exp Biol Med (Maywood). 2001; 226 (5): 409-19.
56. Herrmann S, Paul M. Studying genotype-phenotype relationships: cardiovascular disease as an example. J Mol Med. 2002; 80 (5): 282-9.
57. Nabel E. Cardiovascular disease. N Engl J Med. 2003; 349 (1): 60-72.
58. Schafer AI. Hypercoagulable states: Molecular genetics to clinical practice. Lancet 344:1739-1742, 1994.
59. Nussey S, Whitehead S. Endocrinology: An integrated approach, BIOS Scientific publishers, 2001.
60. Sanders S, Del Mar C. Clever searching for evidence. BMJ. 2005; 330: 1162-3.
61. Ramos K, Linscheid R, Schafer S. Real-time information-seeking behavior of residency physicians. Fam Med 2003; 35: 257-60.
62. Green M, Ruff T. Why do residents fail to answer their clinical questions? A qualitative study of barriers to practicing evidence-based medicine. Acad Med 2005;80:176-82.
63. Tang H, Ng J. Googling for a diagnosis--use of Google as a diagnostic aid: internet based study. BMJ. 2006 Nov 10; PMID: 1709-8763
64. Haynes RB, Wilczynski NL. Optimal search strategies for retrieving scientifically strong studies of diagnosis from Medline: analytical survey. BMJ. 2004;328:1040.
65. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR; Hedges Team. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ. 2005;330:1179.
66. Mishra GR, Suresh M, Kumaran K, Kannabiran N, Suresh S, Bala P, Shivakumar K, Anuradha N et al. Human protein reference database--2006 update. Nucleic Acids Res. 2006;34:D411-4.
67. Smith R. Unscientific practice flourishes in science. BMJ. 1998;316:1036.
68. Kleiner K. Most scientific papers are probably wrong. New Scientist 30 Aug 2005 (http://www.newscientist.com/article.ns?id=dn7915)
69. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005; 2(8):E124.
70. Bacchetti P. Peer review of statistics in medical research: the other problem. BMJ 2002; 324: 1271-1273.
71. Torshin I. Shifting accents: from "anonymous" to "peer review". (http://bmj.bmjjournals.com/cgi/eletters/329/7457/113-c#66360)
72. O'Donnell M. Why doctors don't read research papers: Scientific papers are not written to disseminate information. BMJ, 2005; 330(7485):256.
73. Greenhouse G, Peering into review. Curr. Biol. 10, 23:R849-R850.
74. Glasziou P, Vandenbroucke J, Chalmers I. Assessing the quality of research. BMJ 2004; 328: 39-41.
75. Boynton P, Greenhalgh T. Selecting, designing, and developing your questionnaire. BMJ 2004; 328: 1312-5.
76. Ioannidis JP, Haidich AB, Lau J. Any casualties in the clash of randomised and observational evidence? BMJ 2001;322:879-80.
77. Concato J, Shah N, Horwitz R. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92.
78. Gurwitz J, Sykora K, Mamdani M, Streiner D, Garfinkel S, Normand S, Anderson G, Rochon P. Reader's guide to critical appraisal of cohort studies: 1. Role and design. BMJ 2005; 330: 895-897.
79. Mamdani M, Sykora K, Li P, Normand s, Streiner D, Austin P, Rochon P, Anderson G. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005; 330: 960-962.
80. Normand S, Sykora K, Li P, Mamdani M, Rochon P, Anderson G. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005; 330: 1021-1023.
81. Pastinen T, Perola M, Niini P, Terwilliger J, Salomaa V, Vartiainen E, Peltonen L, Syvanen A. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Genet 1998; 7: 1453-62.
82. Casiglia E, Tikhonoff V, Mazza A, Rynkiewicz A, Limon J, Caffi S, Guglielmi F, Martini B, Basso G, Winnicki M, Pessina AC, Somers VK. C-344T polymorphism of the aldosterone synthase gene and blood pressure in the elderly: a population-based study. J Hypertens. 2005; 23: 1991-6.
83. Safar ME, Cattan V, Lacolley P, Nzietchueng R, Labat C, Lajemi M, de Luca N, Benetos A. Aldosterone synthase gene polymorphism, stroke volume and age-related changes in aortic pulse wave velocity in subjects with hypertension. J Hypertens 2005; 23: 1159-66.
84. More data on the Framingham Heart Study/Framingham Offspring cohorts are available at http://www.nhlbi.nih.gov/resources/deca/descriptions/framoff.htm
85. van Rossum CT, Hoebee B, Seidell JC, Bouchard C, van Baak MA, de Groot CP, Chagnon M, de Graaf C, Saris WH. Genetic factors as predictors of weight gain in young adult Dutch men and women. Int J Obes Relat Metab Disord 2002; 26: 517-28.
86. Mckay R, Oldford R. Scientific Method, Statistical Method, and the Speed of Light. Working Paper 2000-02, Dept of Statistics and Actuarial Science, University of Waterloo. (http://www.stats.uwaterloo.ca/~rwoldfor/papers/sci-method/paperrev.pdf)
87. Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? BMJ. 2001;322:226-31.
88. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998;316:989-91.
89. So-called "Schon scandal", see the entire story at http://en.wikipedia.org/wiki/Jan_Hendrik_Sch%C3%B6n
90. E. Young. Faking it. New Scientist, 12 Dec 2000 (http://www.newscientist.com/article/dn253.html)
91. Abbasi K. The four pillars of global academic medicine. BMJ 2004 Oct 2; 329 (http://www.bmj.com/cgi/content/full/329/7469/0-g?ijkey=5091cdf94d088fcd0e6131204ad3993e536c032b&keytype2=tf_ipsecsha)
92. Fahey T, Griffiths S, Peters TJ. Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ. 1995; 311: 1056-9.
93. Al-Marzouki S, Evans S, Marshall T, Roberts I. Are these data real? Statistical methods for the detection of data fabrication in clinical trials. BMJ 2005; 331: 267-70.
94. Lowe GD, Rumley A, Whincup PH, Danesh J. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med 2002; 2: 429-39.
95. Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, Bahar K, Karayalcin S, Ozden A, Bozkaya H, Yurdaydin C, Uzunalimoglu O. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17: 339-43.
96. Dielis AW, Smid M, Spronk HM, Hamulyak K, Kroon AA, ten Cate H, de Leeuw PW. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension 2005; 46: 1236-42.
97. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher A, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 2004; 109: 178-83.
98. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 1998; 316: 589-92.
99. Kamboh MI, Aston CE, Perez-Tur J, Kokmen E, Ferrell RE, Hardy J, DeKosky ST. A novel mutation in the apolipoprotein E gene (APOE*4 Pittsburgh) is associated with the risk of late-onset Alzheimer's disease. Neurosci Lett. 1999; 263: 129-32.
100. Scacchi R, Gambina G, Ferrari G, Corbo RM. Screening of two mutations at exon 3 of the apolipoprotein E gene (sites 28 and 42) in a sample of patients with sporadic late-onset Alzheimer's disease. Neurobiol Aging 2003; 24: 339-43.
101. Waterworth DM, Talmud PJ, Luan J, Flavell DM, Byrne CD, Humphries SE, Wareham NJ. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta 2003; 1637: 200-6.
102. Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, Tsai AW, Yanez ND, Rosamond WD. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 2002; 99: 2720-5.
103. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96: 2601-5.
104. Stocks J, Thorn JA, Galton DJ. Lipoprotein lipase genotypes for a common premature termination codon mutation detected by PCR-mediated site-directed mutagenesis and restriction digestion. J Lipid Res 1992; 33: 853-7.
105. Humphries SE, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? Arterioscler Thromb Vasc Biol 2004;24:628-36.
106. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 2003; 327: 557-60.
107. Burzotta F, Paciaroni K, De Stefano V, Crea F, Maseri A, Leone G, Andreotti F. G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12 034 subjects. Heart. 2004; 90: 82-6.
108. Burzotta F, Paciaroni K, De Stefano V, Chiusolo P, Manzoli A, Casorelli I, Leone AM, Rossi E, Leone G, Maseri A, Andreotti F. Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J. 2002; 23: 26-30.
109. Wu A, Tsongalis G. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001; 87: 1361-1366.
110. Ye Z, Liu E, Higgins J, Keavney B, Lowe G, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls. Lancet 2006; 367: 651-58.
111. Zhu M, Weedon J, Clark L. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Card 2000; 86: 1000-5.
112. Hattersley A, McCarthy M. What makes a good genetic association study? Lancet. 2005;366:1315-23.
113. Li W, Dammerman M, Smith J, Metzger S, Breslow J, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96: 2601-5.
114. Waterworth D, Talmud P, Bujac S, Fisher RM, Miller GJ, Humphries SE. Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol 2000; 20: 2663-9.
115. Waterworth DM, Talmud PJ, Luan J, Flavell DM, Byrne CD, Humphries SE, Wareham NJ. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta 2003; 1637: 200-6.
116. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.
117. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, Genest J Jr, Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 569-73.
118. Ghandour H, Chen Z, Selhub J, Rozen R. Mice deficient in methylenetetrahydrofolate reductase exhibit tissue-specific distribution of folates. J Nutr. 2004; 134: 2975-8.
119. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
120. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-28.
121. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
122. Klerk M, Verhoef P, Clarke R, Blom H, Kok F, Schouten E and the MTHFR Studies Collaboration Group. MTHFR 677C/T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288: 2023-2032.
123. Wald D, Law M, Morris J. The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screening. Eur J Card Prev Rehab 2004; 11:250-3.
124. Cronin S, Furie K, Kelly P. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke 2005; 36:1581-7.
125. Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Throm Haemost 2004; 3:292-9.
126. Bender R, Grouven U. Logistic regression models used in medical research are poorly presented. BMJ 1996;313:628.
127. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
128. Ito T, Yasue H, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, Mizuno Y, Kawano H, Ogawa H. Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Hum Genet 2002; 110: 89-94.
129. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol 2001; 54: 979-85.
130. Bathum L, von Bornemann Hjelmborg J, Christiansen L, Madsen JS, Skytthe A, Christensen K. Evidence for an association of methylene tetrahydrofolate reductase polymorphism C677T and an increased risk of fractures: results from a populationbased Danish twin study. Osteoporos Int 2004; 15: 659-64.
131. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
132. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. Genetic polymorphism of 5, 10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032-6.
133. Rodriguez-Esparragon F, Hernandez-Perera O, Rodriguez-Perez JC, Anabitarte A, Diaz-Cremades JM, Losada A, Fiuza D, Hernandez E, Yunis C, Ferrario CM. The effect of methylenetetrahydrofolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine values. Clin Exp Hypertens 2003; 25: 209-20.
134. Inamoto N, Katsuya T, Kokubo Y, Mannami T, Asai T, Baba S, Ogata J, Tomoike H, Ogihara T. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid atherosclerosis depending on smoking status in a Japanese general population. Stroke 2003;34:1628-33.
135. Strauss E, Waliszewski K, Gabriel M, Zapalski S, Pawlak AL. Increased risk of the abdominal aortic aneurysm in carriers of the MTHFR 677T allele. J Appl Genet 2003; 44: 85-93.
136. Anello G, Gueant-Rodriguez RM, Bosco P, Gueant JL, Romano A, Namour B, Spada R, Caraci F, Pourie G, Daval JL, Ferri R. Homocysteine and methylenetetrahydrofolate reductase polymorphism in Alzheimer's disease. Neuroreport 2004; 15: 859-61.
137. Zetterberg H, Zafiropoulos A, Spandidos DA, Rymo L, Blennow K. Gene-gene interaction between fetal MTHFR 677C>T and transcobalamin 776C>G polymorphisms in human spontaneous abortion. Hum Reprod 2003; 18: 1948-50.
138. Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM. MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 285-92.
139. Toffoli G, Gafa R, Russo A, Lanza G, Dolcetti R, Sartor F, Libra M, Viel A, Boiocchi M. Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy. Clin Cancer Res 2003; 9: 743-8.
140. Giovannucci E, Chen J, Smith-Warner SA, Rimm EB, Fuchs CS, Palomeque C, Willett WC, Hunter DJ. Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2003; 12: 970-9.
141. Abbasi K. The four pillars of global academic medicine. BMJ 2004 Oct 2; 329 (http://www.bmj.com/cgi/content/full/329/7469/0-g?ijkey=5091cdf94d088fcd0e6131204ad3993e536c032b&keytype2=tf_ipsecsha)
142. Zhang L, Baumeister RF. Your money or your self-esteem: threatened egotism promotes costly entrapment in losing endeavors. Pers Soc Psychol Bull 2006; 32: 881-93.
143. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B Jr, Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998 ;19:357-60.
144. Dow DJ, Lindsey N, Cairns NJ, Brayne C, Robinson D, Huppert FA, Paykel ES, Xuereb J, Wilcock G, Whittaker JL, Rubinsztein DC. Alpha-2 macroglobulin polymorphism and Alzheimer disease risk in the UK. Nat Genet 1999; 22: 16-7.
145. Rudrasingham V, Wavrant-De Vrieze F, Lambert JC, Chakraverty S, Kehoe P, Crook R, Amouyel P, Wu W, Rice F, Perez-Tur J, Frigard B, Morris JC, Carty S, Petersen R, Cottel D, Tunstall N, Holmans P, Lovestone S, Chartier-Harlin MC, Goate A, Hardy J, Owen MJ, Williams J. Alpha-2 macroglobulin gene and Alzheimer disease. Nat Genet 1999; 22: 17-9.
146. Rogaeva EA, Premkumar S, Grubber J, Serneels L, Scott WK, Kawarai T, Song Y, Hill DL, Abou-Donia SM, Martin ER, Vance JJ, Yu G, Orlacchio A, Pei Y, Nishimura M, Supala A, Roberge B, Saunders AM, Roses AD, Schmechel D, Crane-Gatherum A, Sorbi S, Bruni A, Small GW, Conneally PM, Haines JL, Van Leuven F, St George-Hyslop PH, Farrer LA, Pericak-Vance MA. An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat Genet 1999; 22: 19-22.
147. Zappia M, Cittadella R, Manna I, Nicoletti G, Andreoli V, Bonavita S, Gambardella A, Quattrone A. Genetic association of alpha2-macroglobulin polymorphisms with AD in southern Italy. Neurology 2002; 59: 756-8.
148. Nacmias B, Tedde A, Cellini E, Forleo P, Orlacchio A, Guarnieri BM, Petruzzi C, D'Andrea F, Serio A, Sorbi S. Alpha2-macroglobulin polymorphisms in Italian sporadic and familial Alzheimer's disease. Neurosci Lett 2001; 299: 9-12.
149. Alvarez V, Alvarez R, Lahoz CH, Martinez C, Pena J, Guisasola LM, Salas-Puig J, Moris G, Uria D, Menes BB, Ribacoba R, Vidal JA, Sanchez JM, Coto E. Association between an alpha(2) macroglobulin DNA polymorphism and late-onset Alzheimer's disease. Biochem Biophys Res Commun 1999; 264: 48-50.
150. de Groote P, Lamblin N, Helbecque N, Mouquet F, Mc Fadden E, Hermant X, Amouyel P, Dallongeville J, Bauters C. The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail 2005; 7: 966-73.
151. Aggarwal K, Lee K. Functional genomics and proteomics as a foundation for systems biology. Brief Funct Genomic Proteomic 2003; 2: 175-84.
152. Unglaub D, Silverthorn P. Human Physiology: An Integrated Approach. Prentice Hall, 1st ed (1997)
153. Bilello J. The agony and ecstasy of "OMIC" technologies in drug development. Curr Mol Med 2005; 5: 39-52.
154. Ideker T, Thorsson V, Ranish J et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001; 292: 929-934.
155. Xiong M, Feghali-Bostwick CA, Arnett FC, Zhou X. A systems biology approach to genetic studies of complex diseases. FEBS Lett 2005; 579: 5325-32.
156. Jimenez S, Derk C. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37-50.
157. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 1956-63.
158. Rychly J, Nebe B. Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction. Curr Pharm Des. 2006; 12 (29): 3799-806.
159. Evans G, Wheeler C, Corbett J, Dunn M. Construction of HSC-2DPAGE: a twodimensional gel electrophoresis database of heart proteins. Electrophoresis. 1997;18:471-9. http://www.doc.ic.ac.uk/vip/hsc-2dpage/
160. Pleissner K, Sander S, Oswald H, Regitz-Zagrosek V, Fleck E. The construction of the World Wide Web-accessible myocardial two-dimensional gel electrophoresis protein database "HEART-2DPAGE": a practical approach. Electrophoresis 1996;17:1386-92. http://userpage.chemie.fu-berlin.de/~pleiss/
161. Veerasingham S, Sellers K, Raizada M. Functional genomics as an emerging strategy for the investigation of central mechanisms in experimental hypertension. Prog Biophys Mol Biol 2004; 84: 107-23.
162. Borozdenkova S, Westbrook J, Patel V, Wait R, Bolad I, Burke M, Bell AD, Banner N, Dunn M, Rose M. Use of proteomics to discover novel markers of cardiac allograft rejection. J Proteome Res 2004; 3: 282-8.
163. Mata J, Marguerat S, Bahler J. Post-transcriptional control of gene expression: a genome-wide perspective. Trends Biochem Sci 2005; 30: 5-14.
164. Yang E, van Nimwegen E, Zavolan M, Rajewsky N, Schroeder M, Magnasco M, Darnell J. Decay rates of human mRNAs: correlation with functional characteristics and sequence attributes. Genome Res 2003; 13: 1863-72.
165. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski M et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2006 Dec6; doi:10.1038/nature05453
166. Hanash S. Building a Foundation for the Human Proteome: The Role of the Human Proteome Organization. J Proteome Res 2004; 3: 197-199.
167. Xu X, Leow C, Lu X, Zhang X, Liu J, Wong W, Asperger A, Deininger S, Eastwood Leung H. Molecular classification of liver cirrhosis in a rat model by proteomics and bioinformatics. Proteomics 2004; 4: 3235-45.
168. Yan W, Lee H, Yi EC, Reiss D, Shannon P, Kwieciszewski BK, Coito C, Li X, Keller A et al. System-based proteomic analysis of the interferon response in human liver cells. Genome Biol 2004;5:R54
169. Gomes M, Deitcher S. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164: 1965-76.
170. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002 ;288:58-66.
171. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998; 57: 291-301.
172. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575-82.
173. Farquhar C, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA; Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005;3:CD004143
174. Prentice R, Langer R, Stefanick M, Howard B, Pettinger M, Anderson G et al; Women's Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162: 404-14.
175. Nussey S, Whitehead S. Endocrinology: an integrated approach. BIOS Scientific publishers, 2001.
176. Menon D, Vongpatanasin W. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat Endocrinol 2006; 5: 37-51.
177. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric 2004; 7: 347-56.
178. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001; 184: 255-63.
179. Crook D. The metabolic consequences of treating postmenopausal women with nonoral hormone replacement therapy. Br J Obstet Gynaecol 1997;104(S)16:4-13.
180. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35(9):18S-24S.
181. Ockrim J, Lalani el-N, Kakkar A, Abel P. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 2005; 174: 527-33.
182. Douketis J. Hormone replacement therapy and risk for venous thromboembolism: what's new and how do these findings influence clinical practice? Curr Opin Hematol 2005;12:395-400.
183. Lehninger A, Nelson D, Cox M. Principles of biochemistry (2nd ed). Worth Publishers Inc., NY, 1997, p. 779
184. Lowe G. Hormone replacement therapy: prothrombotic vs. protective effects. Pathophysiol Haemost Thromb 2002; 32: 329-32.
185. Samsioe G. Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 1994; 170: 1523-7.
186. Borgfeldt C, Li C, Samsioe G. Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. Climacteric 2004; 7: 78-85.
187. Neaud V, Duplantier JG, Mazzocco C, Kisiel W, Rosenbaum J. Thrombin upregulates tissue factor pathway inhibitor-2 synthesis through a cyclooxygenase-2-dependent, epidermal growth factor receptor-independent mechanism. J Biol Chem 2004; 279: 5200-6.
188. Brueckmann M, Horn S, Lang S, Fukudome K, Schulze Nahrup A, Hoffmann U, Kaden JJ, Borggrefe M, Haase K, Huhle G. Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1. Thromb Haemost 2005; 93: 743-50.
189. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000; 275: 6580-5.
190. Chen C, Lee W, Safe S. Egr-1 is activated by 17beta-estradiol in MCF-7 cells by mitogen-activated protein kinase-dependent phosphorylation of ELK-1. J Cell Biochem 2004; 93: 1063-74.
191. Moverare S, Skrtic S, Lindberg M, Dahlman-Wright K, Ohlsson C. Estrogen increases coagulation factor V mRNA levels via both estrogen receptor-alpha and-beta in murine bone marrow/bone. Eur J Endocrinol 2004; 151: 259-63.
192. Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, Sacchi A, Pontecorvi A. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 1995; 136: 5076-83.
193. Smith L, Coats S, Qin H, Petrie M, Covington J, Su M, Eren M, Vaughan D. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells. Circ Res 2004; 95:269-75.
194. Sumi D, Ignarro L. Estrogen-related receptor alpha 1 up-regulates endothelial nitric oxide synthase expression. Proc Natl Acad Sci USA 2003; 100: 14451-6.
195. Hyder S, Nawaz Z, Chiappetta C, Stancel G. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000; 60: 3183-90.
196. Zhao YY, Sun KL, Ashok K. Analysis of a cis-acting element involved in regulation by estrogen of human angiotensinogen gene expression. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 1998; 30: 445-448.
197. Zhang X, Jiao J, Bhavnani B, Tam S. Regulation of human apolipoprotein A-I gene expression by equine estrogens. J Lipid Res 2001; 42: 1789-800.
198. Rickard D, Hofbauer L, Bonde S, Gori F, Spelsberg T, Riggs B. Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen. J Clin Invest 1998; 101: 413-22.
199. Kanda N, Watanabe S. 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol 2004; 123: 319-28.
200. Tamura M, Deb S, Sebastian S, Okamura K, Bulun S. Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril 2004; 81: 1351-6.
201. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 2004; 64: 3119-25.
202. Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension 1998; 31: 582-8.
203. Krieg A, Krieg S, Ahn B, Shapiro D. Interplay between estrogen response element sequence and ligands controls in vivo binding of estrogen receptor to regulated genes. J Biol Chem 2004; 279: 5025-34.
204. Citarella F, Misiti S, Felici A, Farsetti A, Pontecorvi A, Fantoni A. Estrogen induction and contact phase activation of human factor XII. Steroids 1996; 61: 270-6.
205. Lopez D, Sanchez M, Shea-Eaton W, McLean M. Estrogen activates the high-density lipoprotein receptor gene via binding to estrogen response elements and interaction with sterol regulatory element binding protein-1A. Endocrinology 2002; 143: 2155-68.
206. Seely J, Amigh K, Suzuki T, Mayhew B, Sasano H, Giguere V, Laganiere J, Carr B, Rainey W. Transcriptional regulation of dehydroepiandrosterone sulfotransferase (SULT2A1) by estrogen-related receptor alpha. Endocrinology 2005; 146: 3605-13.
207. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-81.
208. DeNardo D, Kim H, Hilsenbeck S, Cuba V, Tsimelzon A, Brown P. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol 2005; 19: 362-78.
209. Roitt I, Brostoff J, Mosby D. Immunology 5th edn, L Crowe (ed), London, 1998, pp. 99-211.
210. Jansen H, Verhoeven A, Sijbrands E. Hepatic lipase: a pro-or anti-atherogenic protein? J Lipid Res 2002;43:1352-62.
211. Kim J, Dang C. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005 Mar;30:142-50.
212. Torshin IY. Activating oligomerization as intermediate level of signal transduction: analysis of protein-protein contacts and active sites in several glycolytic enzymes. Front Biosci 1999; 4: 557-70.
213. Klee G. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B(12) and folate. Clin Chem 2000; 46: 1277-83.
214. Mikael L, Genest J, Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 2006; 98: 564-71.
215. Oberbeck R. Catecholamines: physiological immunomodulators during health and illness. Curr Med Chem 2006; 13: 1979-89.
216. Kukreja R, Datta B, Chakravarti R. Catecholamine-induced aggravation of aortic and coronary atherosclerosis in monkeys. Atherosclerosis 1981; 40: 291-8.
217. Stampfer M, Malinow M, Willett W, Newcomer L, Upson B, Ullmann D, Tishler P, Hennekens C. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.
218. Selhub J, Jacques P, Bostom A, D'Agostino R, Wilson P, Belanger A, O'Leary D, Wolf P, Rush D, Schaefer E, Rosenberg I. Relationship between plasma homocysteine, vitamin status and extracranial carotid-artery stenosis in the Framingham Study population. J. Nutr 1996;126:1258S-65S.
219. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745-9.
220. Heux S, Morin F, Lea RA, Ovcaric M, Tajouri L, Griffiths L. The methylentetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. Hypertens Res 2004; 27: 663-7.
221. Mendis S, Athauda SB, Naser M, Takahashi K. Association between hyperhomocysteinaemia and hypertension in Sri Lankans. J Int Med Res 1999; 27: 38-44.
222. Mayer E, Jacobsen D, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-27.
223. Harker L, Slichter S, Scott C, Ross R. Homocystinemia, vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-43.
224. Harker L, Ross R, Slichter S, Scott C. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-41.
225. Harker L, Harlan J, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731-9.
226. Zhu B. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. Histol Histopathol 2002; 17: 1283-91.
227. Clarke S, Banfield K. S-adenosylmethionine-dependent methyltransferases. In: Carmel R, Jacobson DW, eds. Homocysteine in Health and Disease. Cambridge: Cambridge Press; 2001.
228. Papin J, Price N, Wiback S, Fell D, Palsson B. Metabolic pathways in the postgenome era. Trends Biochem Sci 2003; 28: 250-8.
229. Reed M, Nijhout H, Neuhouser M, Gregory J, Shane B, James S, Boynton A, Ulrich C. A mathematical model gives insights into nutritional and genetic aspects of folatemediated one-carbon metabolism. J Nutr 2006; 136: 2653-61.
230. Kelly K. Out of Control: The New Biology of Machines, Social Systems and the Economic World. Perseus Books Group NY 1995
231. Breitlinga R, Hoeller D. Current challenges in quantitative modeling of epidermal growth factor signaling. FEBS Lett 2005; 579: 6289-6294.
232. Strange K. The end of "naive reductionism": rise of systems biology or renaissance of physiology? Am J Physiol Cell Physiol 2005;288:C968-74.
233. Cesareni G, Ceol A, Gavrila C, Palazzi L, Persico M, Schneider M. Comparative interactomics. FEBS Lett 2005; 579: 1828-1833.
234. Alm E, Arkin A. Biological networks. Curr Opin Struct Biolo 2003; 13: 193-202.
235. Klemm J, Schreiber S, Crabtree G. Dimerization as a regulatory mechanism in signal transduction. Annu Rev Immunol 1998; 16: 569-92.
236. Ma H, Zeng A. The connectivity structure, giant strong component and centrality of metabolic networks. Bioinformatics 2003; 19: 1423-30.
237. Nielsen J, Oliver S. The next wave in metabolome analysis. Trends Biotechnol 2005; 23: 544-6.
238. Palumbo M, Colosimo A, Giuliani A, Farina L. Functional essentiality from topology features in metabolic networks: a case study in yeast. FEBS Lett 2005; 579:4642-6.
239. Guet C, Elowitz M, Hsing W, Leibler S: Combinatorial synthesis of genetic networks. Science 2002, 296:1466-1470.
240. Berhane B, Zong C, Liem D, Huang A, Le S, Edmondson R, Jones R, Qiao X, Whitelegge J, Ping P, Vondriska T. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 2005; 5: 3520-30.
241. Misek D, Kuick R, Wang H, Galchev V, Deng B, Zhao R, Tra J et al. A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics 2005; 5: 3343-52.
242. Fan Z, Larson P, Bognacki J, Raghunath P, Tomaszewski J, Kuo A, Canziani G, Chaiken I, Cines D, Higazi A. Tissue factor regulates plasminogen binding and activation. Blood 1998; 91: 1987-98.
243. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
244. Byzova T, Plow E. Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin. J Cell Biol 1998;143:2081-92. PMID: 9864377 PubMed-indexed for MEDLINE]
245. Bradford H, Pixley R, Colman R. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem 2000; 275: 22756-63.
246. Pipe S, Morris J, Shah J, Kaufman R. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 1998; 273: 8537-44.
247. Cunningham M, Pipe S, Zhang B, Hauri H, Ginsburg D, Kaufman R. LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost 2003; 1: 2360-7.
248. Weckwerth W, Morgenthal K. Metabolomics: from pattern recognition to biological interpretation. Drug Discov Today 2005; 10: 1551-1558.
249. Rochfort S. Metabolomics reviewed: a new "omics" platform technology for systems biology and implications for natural products research. J Nat Prod 2005; 68: 1813-20.
250. Goodacre R, Vaidyanathan S, Dunn W, Harrigan G, Kell D. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 2004; 22: 245-52.
251. Nielsen J, Oliver S. The next wave in metabolome analysis. Trends Biotechnol 2005; 23: 544-6.
252. Keun H. Metabonomic modeling of drug toxicity. Pharmacol Ther 2006; 109: 92-106.
253. Lee W, Go V. Nutrient-gene interaction: tracer-based metabolomics. J Nutr 2005;135:3027S-3032S.
254. Young VR. Trace element biology: the knowledge base and its application for the nutrition of individuals and populations. J Nutr 2003;133:1581S-7S.
255. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita K, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006;34:D354-7.
256. Caspi R, Foerster H, Fulcher CA, Hopkinson R, Ingraham J, Kaipa P, Krummenacker M, Paley S, Pick J, Rhee SY, Tissier C, Zhang P, Karp PD. MetaCyc: a multiorganism database of metabolic pathways and enzymes. Nucleic Acids Res 2006 ;34:D511-6.
257. Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, de Bono B, Jassal B, Gopinath GR, Wu G, Matthews L, Lewis S, Birney E, Stein L. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 2005;33:D428-32.
258. Karp P, Ouzounis C, Moore-Kochlacs C, Goldovsky L, Kaipa P, Ahren D, Tsoka S, Darzentas N, Kunin V, Lopez-Bigas N. Expansion of the BioCyc collection of pathway/genome databases to 160 genomes. Nucleic Acids Res 2005; 33: 6083-9.
259. Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M, Karp PD. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol 2005;6:R2
260. Arrow K, Gelband H, Jamison D. Making antimalarial agents available in Africa. N Engl J Med 2005; 353: 333-5.
261. White N. Malaria--time to act. N Engl J Med 2006; 355: 1956-7.
262. DiMasi J, Hansen R, Grabowski H. The price of innovation: new estimates of drug development costs. J Health Econ 2005; 22: 151-185.
263. Goozner M. The $800 million pill: the truth behind the cost of new drugs. University of California Press, Berkeley, 2004.
264. Baird J. Effectiveness of antimalarial drugs. N Engl J Med 2005; 352: 1565-77.
265. R. Khamsi. Drug-makers to withdraw single-drug malaria treatment. New Scientist, 12 May 2006 (web reference: http://www.newscientist.com/article/dn9153-drugmakers-to-withdraw-singledrug-malaria-treatment.html)
266. Magill A, Panosian C. Making antimalarial agents available in the United States. N Engl J Med 2005; 353: 335-7.
267. Horrocks P, Bowman S, Kyes S, Waters A, Craig A. Entering the post-genomic era of malaria research. Bull World Health Organ 2000; 78: 1424-37.
268. Di Girolamo F, Raggi C, Bultrini E, Lanfrancotti A, Silvestrini F, Sargiacomo M, Birago C, Pizzi E, Alano P, Ponzi M. Functional genomics, new tools in malaria research. Ann Ist Super Sanita 2005; 41: 469-77.
269. Hall N, Carlton J. Comparative genomics of malaria parasites. Curr Opin Genet Dev 2005; 15: 609-13.
270. Le Roch K, Zhou Y, Blair P, Grainger M, Moch J, Haynes J, de la Vega P, Holder A, Batalov S et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 2003; 301:1503-1508.
271. Le Roch K, Johnson J, Florens L, Zhou Y, Santrosyan A, Grainger M, Yan S et al. Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle. Genome Res 2004; 14: 2308-2318.
272. Bozdech Z, Zhu J, Joachimiak M, Cohen F, Pulliam B, DeRisi J. Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a longoligonucleotide microarray. Genome Biol 2003;4:R9.
273. Gunasekera A, Patankar S, Schug J, Eisen G, Wirth D. Drug-induced alterations in gene expression of the asexual blood forms of Plasmodium falciparum. Mol Microbiol 2003; 50: 1229-39.
274. Myrick A, Munasinghe A, Patankar S, Wirth D. Mapping of the Plasmodium falciparum multidrug resistance gene 5'-upstream region, and evidence of induction of transcript levels by antimalarial drugs in chloroquine sensitive parasites. Mol Microbiol 2003; 49: 671-83.
275. Florens L, Washburn M, Raine J, Anthony R, Grainger M, Haynes J, Moch J, Muster N, Sacci J, Tabb D, Witney A, Wolters D, Wu Y, Gardner M, Holder A, Sinden R, Yates J, Carucci D. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002; 419: 520-6.
276. Lasonder E, Ishihama Y, Andersen J, Vermunt A, Pain A, Sauerwein R, Eling W, Hall N, Waters A, Stunnenberg H, Mann M. Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 2002; 419: 537-42.
277. Sinden R. A proteomic analysis of malaria biology: integration of old literature and new technologies. Int J Parasitol 2004; 34: 1441-50.
278. Torshin IY. New anti-malarial drugs: post-genomic bioinformatics. 2nd Modern Drug Discovery and Development Summit, Dec 4-6, 2006, Philadelphia, PA, USA.
279. Zhang L, Baumeister RF. Your money or your self-esteem: threatened egotism promotes costly entrapment in losing endeavors. Pers Soc Psychol Bull 2006; 32: 881-93.
280. E. Young. Faking it. New Scientist, 12 Dec 2000 http://www.newscientist.com/article/dn253.html)
281. Smith R. Unscientific practice flourishes in science. BMJ 1998;316:1036.
282. Ioannidis JP. Why most published research findings are false. PLoS Med 2005; 2 (8): e124.
283. Committee on Quality of Health Care in America, L Kohn, J Corrigan, M Donaldson (eds). To Err Is Human: Building a Safer Health System. Institute of Medicine (2000), http://books.nap.edu/books/03090681/html/index.html
284. Arrow K, Gelband H, Jamison D. Making antimalarial agents available in Africa. N Engl J Med 2005; 353: 333-5.
285. Magill A, Panosian C. Making antimalarial agents available in the United States. N Engl J Med 2005; 353: 335-7.